Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Haisco Pharmaceutical Group Co. Ltd. has described bromodomain-containing protein 9 (BRD9) inhibitors or BRD9 degradation inducers reported to be useful for the treatment of cancer.
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) rocketed to $11.07 Friday, up $127% or $6.21, on updated data rolled out at the American Society of Clinical Oncology (ASCO) meeting, held virtually this year.